medRxiv copyright holder for this o display the preprint in preprint

/ preprint doi: https://doi.org/10.1101/2024.01.24.24301711; this version posted January 24, 2024. The copyright hold (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the p perpetuity. It is made available under a CC-BY 4.0 International license.
Associations of onset age of breast cancer with incident myocardial infarction
and heart failure: a prospective cohort study
Jie Liang, BS ¹ ; Yang Pan, BS ¹ ; Wenya Zhang, BS ¹ ; Darui Gao, MJC ^{2,3} ; Yongqian
Wang, PhD ^{2,3} ; Wuxiang Xie, PhD ^{2,3} ; Fanfan Zheng, PhD ¹
Affiliations
¹ School of Nursing, Chinese Academy of Medical Sciences & Peking Union Medical
College, Beijing, China;
² Peking University Clinical Research Institute, Peking University First Hospital,
Beijing, China;
³ Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of

12 Education.

13

1

2

3

4

5

6

7

8

9

10

11

Address for correspondence 14

Wuxiang Xie, PhD, FACC, Peking University Clinical Research Institute, Peking 15

16 University First Hospital, No. 38 Xueyuan Road, Haidian District, 100191, Beijing,

17 China.

18 Orcid: 0000-0001-7527-1022.

19 Telephone: +86-10-82805836-622; E-mail: xiewuxiang@hsc.pku.edu.cn;

- 21 Fanfan Zheng, PhD, Department of Clinical Nursing, School of Nursing, Peking
- 22 Union Medical College, No. 33 Ba Da Chu Road, Shijingshan District, 100144,
- 23 Beijing, China.
- 24 Orcid: 0000-0003-2767-2600.
- 25 Telephone: +86-10-88771099; E-mail: zhengfanfan@nursing.pumc.edu.cn.

27 Abstract

28 Background

- 29 The associations of age at breast cancer onset with incident myocardial infarction (MI)
- 30 and heart failure (HF) remain unexamined. Addressing this problem could promote
- 31 understanding of the cardiovascular impact of breast cancer.

32 Methods

- 33 Data were from the UK Biobank. Information on diagnosis of breast cancer, MI and
- 34 HF were collected at baseline and follow-ups (median=12.8 years). Propensity score
- 35 matching method and Cox proportional hazards models were employed.

36 **Results**

- A total of 251,277 female participants (mean age: 56.8±8.0 years), of whom 16,241
- 38 had breast cancer, were included. Among participants with breast cancer, younger
- 39 onset age (per 10-year decrease) was significantly associated with elevated risks of
- 40 MI (HR=1.36, 95%CI: 1.19 to 1.56, *P*<0.001) and HF (HR=1.31, 95% CI: 1.18 to
- 41 1.46, *P*<0.001). After propensity score matching, breast cancer patients with younger

42 onset age had significantly higher risks of MI and HF than healthy controls.

43 Conclusion

- 44 Younger onset age of breast cancer was associated with higher risks of incident MI
- 45 and HF, underscoring the necessity to pay additional attention to the cardiovascular
- 46 health of breast cancer patients diagnosed at younger age to conduct timely
- 47 intervention to attenuate the subsequent risks of incident cardiovascular diseases.
- 48 Key Words

- 49 UK Biobank, breast cancer, onset age, myocardial infarction, heart failure, propensity
- 50 score matching.

51 Introduction

52	Globally, breast cancer is the most commonly diagnosed cancer in women, with 2.3
53	million estimated new cases in 2020.(Sung et al., 2021) Early screening and treatment
54	advancements have resulted in increasing survival,(American Cancer Society, 2019;
55	Berry et al., 2005) as more than 80% of breast cancer patients survive for at least 5
56	years worldwide and nearly 50% of patients survive for 10 years in high-income
57	settings.(Allemani et al., 2018; Cancer Research UK, 2019) However, concerns have
58	been raised about long-term comorbidities, particularly cardiovascular disease (CVD),
59	in breast cancer patients along with the prolonged survival period.(Armenian et al.,
60	2016; Barish et al., 2019; Blaes and Konety, 2021; Florido et al., 2022) CVD poses a
61	major threat to health and is the predominant cause of death in breast cancer
62	patients,(Patnaik et al., 2011) possibly driven by the natural aging process, shared risk
63	factors, and therapy-associated cardiotoxicity.(Khouri et al., 2012; Koene et al., 2016;
64	Yeh and Bickford, 2009) For instance, cardiotoxicity induced by anthracycline-based
65	chemotherapy has been repeatedly reported as an adverse effect of breast cancer
66	treatment.(Du et al., 2009; Lin and Lengacher, 2019) Previous studies focused on the
67	subsequent CVD risk after breast cancer diagnosis revealed that patients had an
68	excess risk of myocardial infarction (MI) and heart failure (HF).(Khan et al., 2011;
69	Reding et al., 2022; Yang et al., 2022)
70	Improvements in breast cancer screening also resulted in an increase in patients
71	diagnosed at younger age. The association of breast cancer with HF was found to be
72	affected by age, as an increased risk of HF was observed only in younger

73	patients.(Lee et al., 2020) Thus, we assumed that the onset age of breast cancer could
74	have an impact on CVD incidence. To date, whether younger age at breast cancer
75	onset is associated with elevated risks of developing MI and HF remains unexplored.
76	Therefore, by using data from the UK Biobank, of which data on onset age of breast
77	cancer and date of incident MI and HF were collected over a relatively long period,
78	this study aimed to investigate the associations of age at breast cancer onset with
79	subsequent risks of incident MI and HF.
80	
81	Materials and methods
82	Study design and population
83	The UK Biobank is a prospective cohort involving sociodemographic and health
84	information of over 270,000 female adults aged 40 and over in the UK. Baseline data
85	were collected between 2006 and 2010. A detailed description of the design and
86	sampling method of the UK Biobank can be found elsewhere.(Hewitt et al., 2016;
87	Sudlow et al., 2015) The UK Biobank has obtained ethical consent from the National
88	Information Governance Board for Health and Social Care and the NHS North West
89	Multicenter Research Ethics Committee. Written informed consent was received from
90	all participants.
91	Figure 1 presents the process of participant selection. Briefly, among the 273,325
92	female adults assessed at baseline, participants with MI or HF at baseline (n=2,992),
93	without complete data on low-density lipoprotein cholesterol (LDL-C; n=18,912), or
94	having MI or HF prior to breast cancer during follow-ups (n=144) were excluded. The

05	
95	remaining 251,277 participants were included in the analyses to investigate the
96	associations of breast cancer with incident MI and HF. Then, 16,241 participants with
97	data on age at breast cancer onset were included in the analyses to evaluate the
98	associations of age at breast cancer onset with incident MI and HF. Finally, 16,241
99	participants with breast cancer and their matched healthy controls (1:3; n=48,723)
100	were included in the propensity score matching analyses to evaluate the associations
101	between breast cancer and incident outcomes among different onset age groups.
102	Ascertainment of breast cancer and age at breast cancer onset
103	Breast cancer and its onset age were identified using the cancer registry data with the
104	International Classification of Diseases Tenth Revision (ICD-10) codes of C50, which
105	acquire information on cancer diagnoses from a variety of sources, including hospitals,
106	cancer centers and treatment centers, cancer screening programs, hospices and nursing
107	homes, etc. Detailed information is presented in Table S1.
108	Ascertainment of MI and HF
109	Algorithmically defined MI with date of diagnosis were ascertained using
110	self-reported data, hospital inpatient records, and mortality register data in the UK
111	Biobank. The earliest record of MI from these sources was considered as the first
112	occurrence date. For HF, the UK Biobank working group has provided the first
113	occurrence date of HF with the ICD-10 codes of I50. Information on outcomes is
114	detailed in Table S2. All outcomes were followed up to December 31, 2021.
115	Covariates

116	Covariates included age, ethnicity (white or nonwhite), educational level (higher
117	educational level or not), current smoking (yes or no), current drinking (≥once per
118	week), exercise, obesity, LDL-C, depressed mood, hypertension, diabetes,
119	antihypertensive drug use (yes or no), antidiabetic drug use (yes or no), and statin use
120	(yes or no). A higher educational level was defined as a college or university degree or
121	other professional qualifications. Exercise was defined as participating in moderate or
122	vigorous physical activity for ≥ 10 minutes at least twice per week. Depressed mood
123	was defined if a participant reported feeling down, depressed, or hopeless nearly
124	every day or more than half the days over the past two weeks. Hypertension was
125	defined as systolic blood pressure (SBP) ≥140 mmHg, diastolic blood pressure (DBP)
126	\geq 90 mmHg, self-reported onset of hypertension, or use of antihypertensive
127	medications. Diabetes was defined as glycated hemoglobin \geq 6.5%, self-reported onset
128	of diabetes, or use of antidiabetic therapy. Obesity was defined as a body mass index
129	\geq 30 kg/m ² . Detailed information on covariates is presented in Table S3 .
130	Statistical analysis
131	Baseline characteristics are presented as the mean±standard deviation for continuous
132	variables and percentages for categorical variables. The effect sizes of differences in
133	baseline characteristics between participants with and without breast cancer are
134	presented as standardized mean differences for continuous outcomes and the Phi
135	coefficient for dichotomous outcomes, with standardized mean difference or the Phi
136	coefficient < -0.1 or >0.1 considered significant. Cox proportional hazards models

137 were applied to evaluate the associations of breast cancer and its onset age with

138	incident MI and HF. Years since baseline (2006-2010) to the first occurrence date of
139	MI or HF, death, loss of follow-up, or the end of follow-up (December 31, 2021),
140	whichever came first, was the time scale in the Cox proportional hazards models. First,
141	we examined the associations of breast cancer with subsequent MI and HF among the
142	total population ($n=251,277$). Second, we tested the associations of age at breast
143	cancer onset with MI and HF among participants with breast cancer (n=16,241). Third,
144	we divided breast cancer participants into three groups according to age at onset: <50
145	years (n=2,674), 50 to 59 years (n=5,637), and ≥ 60 years (n=7,930). Then, three
146	matched healthy controls (1:3) were randomly selected for each breast cancer
147	participant from participants without breast cancer by using the propensity score
148	method,(Parsons, 2004) which accounted for age, ethnicity, education, current
149	smoking, current drinking, obesity, exercise, LDL-C, depressed mood, hypertension,
150	diabetes, antihypertensive drug use, antidiabetic drug use, and statin use. The
151	associations of breast cancer with incident MI and HF were analyzed in three age
152	groups. The method of matching breast cancer patients with non-breast cancer
153	controls in each onset age group, has been used in previous studies,(Cigolle et al.,
154	2022; Shang et al., 2021) as well as in a prior study of our group.(Zhang et al., 2023)
155	Several sensitivity analyses were performed. First, subgroup analyses were
156	performed to identify potential modifying effects from covariates on the associations
157	of breast cancer and its onset age with incident MI and HF. The Z test proposed by
158	Altman and Bland was used to compare the difference between the two regression
159	coefficients from subgroup analyses.(Altman and Bland, 2003) Second, competing

160	risk models were employed to assess the influence of death as a competing event on
161	the associations of age at breast cancer onset with incident MI and HF.(Austin and
162	Fine, 2017) Third, we excluded outcomes that occurred within 5 years since baseline
163	and repeated our main analyses to control for potential reverse causality. Fourth, we
164	restricted analyses to a subgroup of participants aged ≥ 50 years at baseline since the
165	incidences of MI and HF were relatively low in younger participants. Fifth, we set the
166	deadline of follow-up as December 31, 2019, and repeated main analyses to account
167	for the influence of the COVID-19 pandemic on the diagnosis of breast cancer and
168	outcomes since hospital admission and primary care services to chronic diseases were
169	disrupted significantly during this period. Sixth, we further adjusted for menopausal
170	status, breast cancer surgery, and hormone replacement therapy in the main analyses.
171	Seventh, we added cubic spline curves of the association between onset age of breast
172	cancer and incident MI and HF with onset age of breast cancer as a continuous
173	variable. Eighth, we added Kaplan Meier curves comparing survival probabilities
174	between breast cancer patients and matched controls in each onset group.
175	Statistical analyses were performed with SAS 9.4 (SAS Institute, Cary, NC). All
176	analyses were two-sided, with $P < 0.05$ considered significant.
177	
178	Results

179 Baseline characteristics

180 A total of 251,277 female participants (mean age: 56.8±8.0 years) were included in

the present analyses, of whom 16,241 (6.5%) had breast cancer. The median age at

- 182 diagnosis was 59 years (interquartile range [IQR]: 52-66 years). **Table 1** shows the
- 183 baseline characteristics of the participants, grouped by breast cancer status. Overall,
- 184 participants with breast cancer were older, and had higher SBP levels.
- 185 Associations of breast cancer with incident MI and HF
- 186 During a median follow-up of 12.8 years (IQR: 12.1-13.6 years), 4,549 (1.8%) MI
- 187 and 4,917 (2.0%) HF were identified. As presented in **Table 2**, after adjusting for
- multiple covariates among the total population (n=251,277), breast cancer participants
- 189 exhibited a significantly lower risk of developing MI (hazard ratio [HR]=0.83, 95%
- 190 confidence interval [CI]: 0.73 to 0.94, *P*=0.002) and a significantly higher risk of
- 191 developing HF (HR=1.20, 95% CI: 1.09 to 1.33, *P*<0.001).
- 192 Associations of age at breast cancer onset with incident MI and HF among
- 193 participants with breast cancer
- As shown in **Table 3**, among 16,241 breast cancer participants, age at onset was
- 195 significantly associated with subsequent risks of MI and HF; that is, those diagnosed
- 196 at younger age had higher risks of developing MI (per 10-year decrease: HR=1.36, 95%
- 197 CI: 1.19 to 1.56, *P*<0.001) and HF (per 10-year decrease: HR=1.31, 95% CI: 1.18 to

198 1.46, *P*<0.001).

199 Associations of breast cancer with incident MI and HF among different onset age

- 200 groups based on propensity score matching data
- 201 We then further investigated the relationships between breast cancer and incident
- 202 outcomes in different onset age groups among 16,241 breast cancer participants and
- their matched healthy controls by using propensity score matching analyses. As

204	presented in	Table S4.	after pro	pensity sc	core matching.	no significant	difference was

- 205 detected between participants with and without breast cancer in all covariates. Table 4
- shows that breast cancer diagnosed before 50 years was associated with the highest
- 207 HRs for incident MI and HF compared with those without breast cancer (MI:
- 208 HR=1.75, 95% CI: 1.21 to 2.52, *P*=0.003; HF: HR=2.21, 95% CI: 1.55 to 3.17,
- P < 0.001), followed by breast cancer diagnosed between 50 and 59 years (MI:

210 HR=0.75, 95% CI: 0.58 to 0.97, P=0.028; HF: HR=1.38, 95% CI: 1.13 to 1.69,

- 211 P=0.002), and then breast cancer diagnosed at 60 years and over (MI: HR=0.75, 95%
- 212 CI: 0.63 to 0.89, *P*=0.001; HF: HR=1.03, 95% CI: 0.90 to 1.19, *P*=0.650).

213 Sensitivity analysis

214 As shown in Figures S1-6, the results from subgroup analyses were similar to those 215 from our main analyses. Interestingly, our subgroup analyses found that hypertension and diabetes modified the association of breast cancer with incident HF. Cubic spline 216 curves of the association between onset age of breast cancer and incident MI and HF 217 218 with onset age of breast cancer as a continuous variable and Kaplan Meier curves comparing survival probabilities between breast cancer patients and matched controls 219 220 in each onset group were consistent with our main results (Figures S7-14). As presented in Tables S5-14, the results remained stable after further adjusting for 221 competing risk of death, excluding participants diagnosed with MI or HF within 5 222 years since baseline, excluding participants aged <50 years at baseline, setting the 223 deadline of follow-up as December 31, 2019, or further adjusting for menopausal 224 status, breast cancer, and hormone replacement therapy. 225

226

227 Discussion

228	By using data from the large, prospective cohort of the UK Biobank, this study
229	revealed that breast cancer patients were at a decreased risk of developing MI and an
230	increased risk of developing HF compared to participants without breast cancer. It is
231	worth noting that younger onset age of breast cancer was associated with elevated
232	risks of incident MI and HF among breast cancer patients. After propensity score
233	matching, the strength of the associations gradually increased with descending age at
234	breast cancer onset.
235	Our findings were in line with several recent studies investigating the associations
236	of breast cancer with CVD.(Gue et al., 2022; Strongman et al., 2019) A large cohort
237	study linked to the UK Clinical Practice Research Datalink revealed a decreased risk
238	of incident MI and an increased risk of incident HF in breast cancer patients during an
239	average 7-year follow-up, with HRs of 0.82 and 1.13, respectively, which was close to
240	our results.(Strongman et al., 2019) Another population-based study at the nationwide
241	level in France, with a mean follow-up of 5 years, also demonstrated similar risks of
242	MI and HF.(Gue et al., 2022) The elevated risk of subsequent HF in breast cancer
243	patients has been observed in most studies, which may be related to the cardiotoxic
244	effect on the myocardium induced by anthracycline and trastuzumab.(Abdel-Qadir et
245	al., 2019; Gue et al., 2022; Lee et al., 2020; Reding et al., 2022; Strongman et al.,
246	2019; Yang et al., 2022) The decreased risk of MI observed in the study might be
247	driven by the cardioprotective effects of tamoxifen and socioeconomic factors, as

248	indicated in previous studies,(Grainger and Schofield, 2005; Khosrow-Khavar et al.,
249	2017; Tweed et al., 2018) while the precise mechanisms have not yet been elucidated.
250	However, previous findings with regard to MI or ischemic heart disease were
251	inconsistent, with some researchers reporting increased risk,(Armenian et al., 2016;
252	Rugbjerg et al., 2014) but others observing null results.(Abdel-Qadir et al., 2019;
253	Khan et al., 2011) The discordance may be partly due to heterogeneity in population
254	characteristics, length of follow-ups, and sources of breast cancer and CVD data. For
255	example, the age of the population might influence the association, as indicated by a
256	nationwide cohort study in Korea, which showed that an increased risk of HF only
257	existed in younger breast cancer patients (<50).(Lee et al., 2020) Moreover, the
258	present study extended prior research by comparing the risk of MI and HF among
259	different onset age groups and demonstrated that age at breast cancer onset was an
260	important determinant for the risks of incident MI and HF.
261	To the best of our knowledge, this is the largest study to date to explore the
262	impact of the onset age of breast cancer on the subsequent risks of MI and HF. With
263	accurate data on age at diagnosis of breast cancer and sufficient CVD events over the
264	lengthy follow-up, this study revealed that risks of incident MI and HF increased with
265	decreasing age at breast cancer onset (especially <50). A Danish cohort study focused
266	on patients of adolescent and young adult cancer indicated that breast cancer patients
267	diagnosed at younger age, particularly between 20 and 24 years, had the highest risk
268	of CVD.(Rugbjerg et al., 2014) Similarly, the Teenage and Young Adult Cancer
269	Survivor Study demonstrated that cardiac death risk increased in younger onset age

270	groups, although the trend was not significant.(Henson et al., 2016) Possibly due to a
271	relatively small sample size, a narrow range of onset age, and insufficient CVD events,
272	the trend between onset age of breast cancer and CVD risk was not detected in the
273	two studies, and the results need further verification. The present study addressed
274	these issues by focusing on a population with an onset age ranging from 27 to 82
275	years, while the prior studies were both limited to 15 to 39 years and with nearly
276	10,000 participants diagnosed with MI or HF during the follow-up, providing a robust
277	and reliable finding on the associations of the onset age of breast cancer with MI and
278	HF.
279	Although the mechanisms underlying the associations are still not fully
280	understood, several potential pathways have been proposed. First, younger age was
281	found to be associated with a higher tumor grade and a more aggressive phenotype
282	(e.g., triple-negative breast cancer) in breast cancer patients,(Colleoni et al., 2002; El
283	Saghir et al., 2006; McGuire et al., 2015) for whom anthracycline-containing
284	chemotherapy was the usual therapeutic regimen. Anthracycline is known to confer
285	great cardiotoxicity by harming cardiac myocytes at a cumulative dose, resulting in
286	subsequent CVD.(Greenlee et al., 2022; Hooning et al., 2007; Smith et al., 2010)
287	Second, patients diagnosed at younger age tended to choose breast-conserving surgery,
288	often accompanied by radiotherapy, which was associated with an accelerated
289	coronary calcium burden.(Lai, Chen and Tsai, 2021) A dose-response relationship has
290	been observed between radiotherapy and CVD, with major coronary events increasing
291	by 7.4% per gray.(Darby et al., 2013) Third, younger premenopausal patients were at

000	
292	risk of early menopause induced by chemotherapy,(Zavos and Valachis, 2016) leading
293	to reduced exposure to the cardioprotective effects of estrogen and an elevated risk of
294	developing CVD.(Mendelsohn and Karas, 1999; Wellons et al., 2012; Xu et al., 2006)
295	Furthermore, hormone replacement therapy in postmenopausal women was also
296	associated with increased CVD risk.(Rossouw et al., 2002)
297	This study has several strengths. First, data on the diagnosis of MI and HF were
298	from hospital inpatient records, mortality register data, primary care data, and
299	self-reported data.(UK Biobank Follow-up and Outcomes Working Group, 2022)
300	These multisource data outweighed self-reported data with higher accuracy, as
301	approximately 30% of self-reported CVD cases were misclassified by patients.(Barr
302	et al., 2009) Second, the large sample size of the UK Biobank ensured a robust
303	conclusion on the associations of the onset age of breast cancer with MI and HF with
304	sufficient statistical power. Third, propensity score matching analyses after controlling
305	for multiple traditional risk factors significantly reduced confounding bias.
306	In spite of these strengths, the present study has some limitations. First, a causal
307	relationship cannot be concluded due to the observational study design. Second,
308	22,048 participants were excluded, which might lead to selection bias. Significant
309	differences in LDL-C levels existed between participants included and excluded
310	(Table S15). In general, the participants included were younger and healthier, which
311	might bias the associations observed in this study. Third, even though we have
312	adjusted for many traditional confounders, the possibility of residual confounding
313	cannot be ruled out. For instance, due to a lack of information on staging of breast

314	cancer, radiotherapy and chemotherapy of breast cancer patients in the UK Biobank,
315	we were unable to assess the impact of these potential confounders. Fourth, the study
316	population primarily consisted of the white ethnicity with a proportion of 94.3%,
317	which may not represent the general UK population. Thus, generalization of the
318	findings should be cautious, and validations in other populations are needed.
319	
320	Conclusion
321	This study demonstrated that younger onset age of breast cancer was associated
322	with higher risks of incident MI and HF. This finding has significant implications for
323	clinical and public health, highlighting the need to pay attention to the cardiovascular
324	health of younger breast cancer patients, especially those diagnosed before 50 years
325	old. Further studies with regard to this aspect are warranted and cardiac monitoring
326	strategies need to be developed based on the cardiovascular risk of these individuals.
327	
328	Acknowledgments
329	We appreciate efforts made by the original data creators, depositors, copyright holders,
330	the funders of the data collections, and their contributions to access to data from the
331	UK Biobank, approved project number 90492.
332	Competing interests
333	None.

334 Funding

335	This study was supported by grants from the National Natural Science Foundation of
336	China (82373665 & 81974490), the Nonprofit Central Research Institute Fund of
337	Chinese Academy of Medical Sciences (2021-RC330-001), and the 2022 China
338	Medical Board-open competition research grant (22-466). All authors had no conflict
339	of interest.
340	Author contributions
341	Fanfan Zheng and Wuxiang Xie participated in the study conception and design,
342	supervised the data analysis, reviewed the paper and approved the final draft for
343	submission. Jie Liang participated in the study conception and design, analyzed data,
344	wrote and approved the final draft for submission. All authors reviewed the paper,
345	made critical revision, and approved the final draft for submission.
346	Ethics
347	The UK Biobank has received ethical consent from the North West Multi-centre
348	Research Ethics Committee (MREC) (299116). Written informed consent was
349	obtained from all participants. This research was done without participants
350	involvement.
351	Availability of data and materials
352	The data used for analysis in this study are available from the UK Biobank project site,
353	subject to registration and application processes. Further details can be found at

354 https://www.ukbiobank.ac.uk.

355 **References**

356	Abdel-Qadir, H., Thavendiranathan, P., Austin, P.C., Lee, D.S., Amir, E., Tu, J.V.,
357	Fung, K., Anderson, G.M., 2019. The Risk of Heart Failure and Other
358	Cardiovascular Hospitalizations After Early Stage Breast Cancer: A Matched
359	Cohort Study. J Natl Cancer Inst 111, 854-862. DOI:https://doi.org/
360	10.1093/jnci/djy218
361	Allemani, C., Matsuda, T., Di Carlo, V., Harewood, R., Matz, M., Nikšić, M.,
362	Bonaventure, A., Valkov, M., Johnson, C.J., Estève, J., Ogunbiyi, O.J., Azevedo,
363	E.S.G., Chen, W.Q., Eser, S., Engholm, G., Stiller, C.A., Monnereau, A., Woods,
364	R.R., Visser, O., Lim, G.H., Aitken, J., Weir, H.K., Coleman, M.P., 2018.
365	Global surveillance of trends in cancer survival 2000-14 (CONCORD-3):
366	analysis of individual records for 37 513 025 patients diagnosed with one of 18
367	cancers from 322 population-based registries in 71 countries. Lancet 391,
368	1023-1075. DOI:https://doi.org/ 10.1016/s0140-6736(17)33326-3
369	Altman, D.G., Bland, J.M., 2003. Interaction revisited: the difference between two
370	estimates. BMJ 326, 219. DOI:https://doi.org/ 10.1136/bmj.326.7382.219
371	American Cancer Society, 2019. Breast Cancer Facts and Figures 2019-2020. Am
372	Cancer Soc, 1-44.
373	Armenian, S.H., Xu, L., Ky, B., Sun, C., Farol, L.T., Pal, S.K., Douglas, P.S., Bhatia,
374	S., Chao, C., 2016. Cardiovascular Disease Among Survivors of Adult-Onset
375	Cancer: A Community-Based Retrospective Cohort Study. J Clin Oncol 34,
376	1122-1130. DOI:https://doi.org/ 10.1200/jco.2015.64.0409

- 377 Austin, P.C., Fine, J.P., 2017. Practical recommendations for reporting Fine-Gray
- 378 model analyses for competing risk data. Stat Med 36, 4391-4400.
- 379 DOI:https://doi.org/ 10.1002/sim.7501
- 380 Barish, R., Lynce, F., Unger, K., Barac, A., 2019. Management of Cardiovascular
- 381 Disease in Women With Breast Cancer. Circulation 139, 1110-1120.
 382 DOI:https://doi.org/ 10.1161/circulationaha.118.039371
- 383 Barr, E.L., Tonkin, A.M., Welborn, T.A., Shaw, J.E., 2009. Validity of self-reported
- 384 cardiovascular disease events in comparison to medical record adjudication and
- a statewide hospital morbidity database: the AusDiab study. Intern Med J 39,

386 49-53. DOI:https://doi.org/ 10.1111/j.1445-5994.2008.01864.x

- 387 Berry, D.A., Cronin, K.A., Plevritis, S.K., Fryback, D.G., Clarke, L., Zelen, M.,
- 388 Mandelblatt, J.S., Yakovlev, A.Y., Habbema, J.D., Feuer, E.J., 2005. Effect of
- 389 screening and adjuvant therapy on mortality from breast cancer. N Engl J Med

390 353, 1784-1792. DOI:https://doi.org/ 10.1056/NEJMoa050518

- 391 Blaes, A.H., Konety, S.H., 2021. Cardiovascular Disease in Breast Cancer Survivors:
- An Important Topic in Breast Cancer Survivorship. J Natl Cancer Inst 113,
 105-106. DOI:https://doi.org/ 10.1093/inci/diaa097
- 394 Cancer Research UK, 2019. Cancer statistics for the UK.
 395 https://www.cancerresearchuk.org/health-professional/cancer-statistics-for-the-u
 396 k.
- Cigolle, C.T., Blaum, C.S., Lyu, C., Ha, J., Kabeto, M., Zhong, J., 2022.
 Associations of Age at Diagnosis and Duration of Diabetes With Morbidity and

399	Mortality	Among	Older	Adults.	JAMA	Netw	Open	5,	e2232766.
400	DOI:https:	//doi.org/	10.1001/	/jamanetw	orkopen.	2022.32	766		

- 401 Colleoni, M., Rotmensz, N., Robertson, C., Orlando, L., Viale, G., Renne, G., Luini,
- 402 A., Veronesi, P., Intra, M., Orecchia, R., Catalano, G., Galimberti, V., Nolé, F.,
- 403 Martinelli, G., Goldhirsch, A., 2002. Very young women (<35 years) with
- 404 operable breast cancer: features of disease at presentation. Ann Oncol 13,

405 273-279. DOI:https://doi.org/ 10.1093/annonc/mdf039

- 406 Darby, S.C., Ewertz, M., McGale, P., Bennet, A.M., Blom-Goldman, U., Brønnum,
- 407 D., Correa, C., Cutter, D., Gagliardi, G., Gigante, B., Jensen, M.B., Nisbet, A.,
- 408 Peto, R., Rahimi, K., Taylor, C., Hall, P., 2013. Risk of ischemic heart disease in
- 409 women after radiotherapy for breast cancer. N Engl J Med 368, 987-998.
- 410 DOI:https://doi.org/ 10.1056/NEJMoa1209825
- 411 Du, X.L., Xia, R., Liu, C.C., Cormier, J.N., Xing, Y., Hardy, D., Chan, W., Burau, K.,
- 412 2009. Cardiac toxicity associated with anthracycline-containing chemotherapy
- 413 in older women with breast cancer. Cancer 115, 5296-5308. DOI:https://doi.org/
- 414 10.1002/cncr.24621
- 415 El Saghir, N.S., Seoud, M., Khalil, M.K., Charafeddine, M., Salem, Z.K., Geara, F.B.,
- 416 Shamseddine, A.I., 2006. Effects of young age at presentation on survival in
- 417 breast cancer. BMC Cancer 6, 194. DOI:https://doi.org/
 418 10.1186/1471-2407-6-194
- 419 Florido, R., Daya, N.R., Ndumele, C.E., Koton, S., Russell, S.D., Prizment, A.,
- 420 Blumenthal, R.S., Matsushita, K., Mok, Y., Felix, A.S., Coresh, J., Joshu, C.E.,

421	Platz, E.A., Selvin, E., 2022. Cardiovascular Disease Risk Among Cancer
422	Survivors: The Atherosclerosis Risk In Communities (ARIC) Study. J Am Coll
423	Cardiol 80, 22-32. DOI:https://doi.org/ 10.1016/j.jacc.2022.04.042
424	Grainger, D.J., Schofield, P.M., 2005. Tamoxifen for the prevention of myocardial
425	infarction in humans: preclinical and early clinical evidence. Circulation 112,
426	3018-3024. DOI:https://doi.org/ 10.1161/circulationaha.104.531178
427	Greenlee, H., Iribarren, C., Rana, J.S., Cheng, R., Nguyen-Huynh, M., Rillamas-Sun,
428	E., Shi, Z., Laurent, C.A., Lee, V.S., Roh, J.M., Santiago-Torres, M., Shen, H.,
429	Hershman, D.L., Kushi, L.H., Neugebauer, R., Kwan, M.L., 2022. Risk of
430	Cardiovascular Disease in Women With and Without Breast Cancer: The
431	Pathways Heart Study. J Clin Oncol 40, 1647-1658. DOI:https://doi.org/
432	10.1200/jco.21.01736
433	Gue, Y.X., Bisson, A., Bodin, A., Herbert, J., Lip, G.Y.H., Fauchier, L., 2022. Breast
434	cancer and incident cardiovascular events: A systematic analysis at the

- 435 nationwide level. Eur J Clin Invest 52, e13754. DOI:https://doi.org/
 436 10.1111/eci.13754
- 437 Henson, K.E., Reulen, R.C., Winter, D.L., Bright, C.J., Fidler, M.M., Frobisher, C.,
- 438 Guha, J., Wong, K.F., Kelly, J., Edgar, A.B., McCabe, M.G., Whelan, J., Cutter,
- 439 D.J., Darby, S.C., Hawkins, M.M., 2016. Cardiac Mortality Among 200 000
- 440 Five-Year Survivors of Cancer Diagnosed at 15 to 39 Years of Age: The
- 441 Teenage and Young Adult Cancer Survivor Study. Circulation 134, 1519-1531.
- 442 DOI:https://doi.org/ 10.1161/circulationaha.116.022514

443	Hewitt. J.,	Walters. M.	Padmanabhan	. S	Dawson	J.,	. 2016.	Cohort	profile	of	the

- 444 UK Biobank: diagnosis and characteristics of cerebrovascular disease. BMJ
- 445 Open 6, e009161. DOI:https://doi.org/ 10.1136/bmjopen-2015-009161
- 446 Hooning, M.J., Botma, A., Aleman, B.M., Baaijens, M.H., Bartelink, H., Klijn, J.G.,
- 447 Taylor, C.W., van Leeuwen, F.E., 2007. Long-term risk of cardiovascular
- disease in 10-year survivors of breast cancer. J Natl Cancer Inst 99, 365-375.
- 449 DOI:https://doi.org/ 10.1093/jnci/djk064
- 450 Khan, N.F., Mant, D., Carpenter, L., Forman, D., Rose, P.W., 2011. Long-term health
- 451 outcomes in a British cohort of breast, colorectal and prostate cancer survivors:
- 452 a database study. Br J Cancer 105 Suppl 1, S29-37. DOI:https://doi.org/
 453 10.1038/bjc.2011.420
- 454 Khosrow-Khavar, F., Filion, K.B., Al-Qurashi, S., Torabi, N., Bouganim, N., Suissa,
- 455 S., Azoulay, L., 2017. Cardiotoxicity of aromatase inhibitors and tamoxifen in
- 456 postmenopausal women with breast cancer: a systematic review and
- 457 meta-analysis of randomized controlled trials. Ann Oncol 28, 487-496.

458 DOI:https://doi.org/ 10.1093/annonc/mdw673

- 459 Khouri, M.G., Douglas, P.S., Mackey, J.R., Martin, M., Scott, J.M., Scherrer-Crosbie,
- 460 M., Jones, L.W., 2012. Cancer therapy-induced cardiac toxicity in early breast
- 461 cancer: addressing the unresolved issues. Circulation 126, 2749-2763.
- 462 DOI:https://doi.org/ 10.1161/circulationaha.112.100560
- Koene, R.J., Prizment, A.E., Blaes, A., Konety, S.H., 2016. Shared Risk Factors in
 Cardiovascular Disease and Cancer. Circulation 133, 1104-1114.

465 DOI:https://doi.org/ 10.1161/circulationaha.115.020406

- Lai, Y.H., Chen, H.H.W., Tsai, Y.S., 2021. Accelerated coronary calcium burden in
 breast cancer patients after radiotherapy: a comparison with age and race
 matched healthy women. Radiat Oncol 16, 210. DOI:https://doi.org/
 10.1186/s13014-021-01936-w
- 470 Lee, J., Hur, H., Lee, J.W., Youn, H.J., Han, K., Kim, N.W., Jung, S.Y., Kim, Z., Kim,
- 471 K.S., Lee, M.H., Han, S.H., Jung, S.H., Chung, I.Y., 2020. Long-term risk of
- 472 congestive heart failure in younger breast cancer survivors: A nationwide study
- 473 by the SMARTSHIP group. Cancer 126, 181-188. DOI:https://doi.org/
 474 10.1002/cncr.32485
- 475 Lin, K.J., Lengacher, C.A., 2019. Anthracycline Chemotherapy-Induced
- 476 Cardiotoxicity in Breast Cancer Survivors: A Systematic Review. Oncol Nurs
- 477 Forum 46, E145-e158. DOI:https://doi.org/ 10.1188/19.Onf.E145-e158
- 478 McGuire, A., Brown, J.A., Malone, C., McLaughlin, R., Kerin, M.J., 2015. Effects
- 479 of age on the detection and management of breast cancer. Cancers (Basel) 7,

480 908-929. DOI:https://doi.org/ 10.3390/cancers7020815

- Mendelsohn, M.E., Karas, R.H., 1999. The protective effects of estrogen on the
 cardiovascular system. N Engl J Med 340, 1801-1811. DOI:https://doi.org/
 10.1056/nejm199906103402306
- 484 Parsons, L.S., 2004. Performing a 1: N case-control match on propensity score,
- 485 Proceedings of the 29th Annual SAS users group international conference. SAS
- 486 Institute Montreal, Montreal, Canada, p. e11.

487	Patnaik, J.L., Byers, T., DiGuiseppi, C., Dabelea, D., Denberg, T.D., 2011.
488	Cardiovascular disease competes with breast cancer as the leading cause of
489	death for older females diagnosed with breast cancer: a retrospective cohort
490	study. Breast Cancer Res 13, R64. DOI:https://doi.org/ 10.1186/bcr2901
491	Reding, K.W., Cheng, R.K., Vasbinder, A., Ray, R.M., Barac, A., Eaton, C.B., Saquib,
492	N., Shadyab, A.H., Simon, M.S., Langford, D., Branch, M., Caan, B., Anderson,
493	G., 2022. Lifestyle and Cardiovascular Risk Factors Associated With
494	Heart Failure Subtypes in Postmenopausal Breast Cancer Survivors. JACC
495	CardioOncol 4, 53-65. DOI:https://doi.org/ 10.1016/j.jaccao.2022.01.099
496	Rossouw, J.E., Anderson, G.L., Prentice, R.L., LaCroix, A.Z., Kooperberg, C.,
497	Stefanick, M.L., Jackson, R.D., Beresford, S.A., Howard, B.V., Johnson, K.C.,
498	Kotchen, J.M., Ockene, J., 2002. Risks and benefits of estrogen plus progestin
499	in healthy postmenopausal women: principal results From the Women's Health
500	Initiative randomized controlled trial. JAMA 288, 321-333. DOI:https://doi.org/
501	10.1001/jama.288.3.321
502	Rugbjerg, K., Mellemkjaer, L., Boice, J.D., Køber, L., Ewertz, M., Olsen, J.H., 2014.
503	Cardiovascular disease in survivors of adolescent and young adult cancer: a

- 504 Danish cohort study, 1943-2009. J Natl Cancer Inst 106, dju110.
 505 DOI:https://doi.org/ 10.1093/jnci/dju110
- Shang, X., Hill, E., Zhu, Z., Liu, J., Ge, B.Z., Wang, W., He, M., 2021. The
 Association of Age at Diagnosis of Hypertension With Brain Structure and
 Incident Dementia in the UK Biobank. Hypertension 78, 1463-1474.

509 DOI:https://doi.org/ 10.1161/hypertensionaha.121.17608

- 510 Smith, L.A., Cornelius, V.R., Plummer, C.J., Levitt, G., Verrill, M., Canney, P., Jones,
- 511 A., 2010. Cardiotoxicity of anthracycline agents for the treatment of cancer:
- 512 systematic review and meta-analysis of randomised controlled trials. BMC
- 513 Cancer 10, 337. DOI:https://doi.org/ 10.1186/1471-2407-10-337
- 514 Strongman, H., Gadd, S., Matthews, A., Mansfield, K.E., Stanway, S., Lyon, A.R.,
- Dos-Santos-Silva, I., Smeeth, L., Bhaskaran, K., 2019. Medium and long-term
 risks of specific cardiovascular diseases in survivors of 20 adult cancers: a
 population-based cohort study using multiple linked UK electronic health
 records databases. Lancet 394, 1041-1054. DOI:https://doi.org/
 10.1016/s0140-6736(19)31674-5
- 520 Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P.,
- 521 Elliott, P., Green, J., Landray, M., Liu, B., Matthews, P., Ong, G., Pell, J.,
- 522 Silman, A., Young, A., Sprosen, T., Peakman, T., Collins, R., 2015. UK biobank:
- an open access resource for identifying the causes of a wide range of complex
- diseases of middle and old age. PLoS Med 12, e1001779. DOI:https://doi.org/
- 525 10.1371/journal.pmed.1001779
- 526 Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., Bray,
- 527 F., 2021. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence
- and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71,
- 529 209-249. DOI:https://doi.org/ 10.3322/caac.21660
- 530 Tweed, E.J., Allardice, G.M., McLoone, P., Morrison, D.S., 2018. Socio-economic

- inequalities in the incidence of four common cancers: a population-based
 registry study. Public Health 154, 1-10. DOI:https://doi.org/
 10.1016/j.puhe.2017.10.005
- 534 UK Biobank Follow-up and Outcomes Working Group, 2022. UK Biobank
 535 Algorithmically defined outcomes, Version 2.0 ed.
- 536 Wellons, M., Ouyang, P., Schreiner, P.J., Herrington, D.M., Vaidya, D., 2012. Early
- 537 menopause predicts future coronary heart disease and stroke: the Multi-Ethnic
- 538 Study of Atherosclerosis. Menopause 19, 1081-1087. DOI:https://doi.org/
- 539 10.1097/gme.0b013e3182517bd0
- 540 Xu, Y., Arenas, I.A., Armstrong, S.J., Plahta, W.C., Xu, H., Davidge, S.T., 2006.
- 541 Estrogen improves cardiac recovery after ischemia/reperfusion by decreasing
 542 tumor necrosis factor-alpha. Cardiovasc Res 69, 836-844. DOI:https://doi.org/
- 543 10.1016/j.cardiores.2005.11.031
- 544 Yang, H., Bhoo-Pathy, N., Brand, J.S., Hedayati, E., Grassmann, F., Zeng, E., Bergh,
- 545 J., Bian, W., Ludvigsson, J.F., Hall, P., Czene, K., 2022. Risk of heart disease
- 546 following treatment for breast cancer-results from a population-based cohort
- 547 study. Elife 11. DOI:https://doi.org/ 10.7554/eLife.71562
- 548 Yeh, E.T., Bickford, C.L., 2009. Cardiovascular complications of cancer therapy:
- 549 incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 53,
- 550 2231-2247. DOI:https://doi.org/ 10.1016/j.jacc.2009.02.050
- 551 Zavos, A., Valachis, A., 2016. Risk of chemotherapy-induced amenorrhea in patients
- with breast cancer: a systematic review and meta-analysis. Acta Oncol 55,

553 664-670. DOI:https://doi.org/ 10.3109/0284186x.2016.1155738

- 554 Zhang, W., Liang, J., Li, C., Gao, D., Ma, Q., Pan, Y., Wang, Y., Xie, W., Zheng, F.,
- 555 2023. Age at Diagnosis of Atrial Fibrillation and Incident Dementia. JAMA
- 556 Netw Open 6, e2342744. DOI:https://doi.org/
- 557 10.1001/jamanetworkopen.2023.42744

Table 1. Baseline characteristics of the study participants, by whether they had a 558

history of breast cancer at baseline or incident breast cancer during follow-up 559

(n=251 277) 560

	Breast cancer	Non-breast cancer	Effect
Characteristic	(n=16 241)	(n=235 036)	size ^a
Age, years	58.9±7.3	56.7±8.0	0.275
White	15 619 (96.2)	221 292 (94.2)	0.021
Higher education	7571 (46.6)	109 362 (46.5)	< 0.001
Current smoking	1390 (8.6)	20 764 (8.8)	-0.002
Current drinking	10 451 (64.4)	146 679 (62.4)	0.010
Obesity	3934 (24.2)	54 321 (23.1)	0.007
Exercise	12 506 (77.0)	182 852 (77.8)	-0.005
SBP, mmHg	137.4±19.4	135.1±19.2	0.118
DBP, mmHg	81.4±9.9	80.7±10.0	0.065
HbA _{1c} , %	3.63±0.60	3.57±0.59	0.093
TC, mmol/L	5.95±1.14	5.88±1.12	0.060
HDL-C, mmol/L	1.60±0.38	1.59±0.38	0.008
LDL-C, mmol/L	3.67±0.88	3.63±0.87	0.049
Depressed mood	778 (4.8)	12 351 (5.3)	-0.005
Hypertension	8643 (53.2)	112 667 (47.9)	0.026
Diabetes	795 (4.9)	9883 (4.2)	0.008
Antihypertensive drug use	3203 (19.7)	39 767 (16.9)	0.018

Antidiabetic drug use	449 (2.8)	5628 (2.4)	0.006
Statin use	1885 (11.6)	24 502 (10.4)	0.010

- 561 The results are presented as the mean±standard deviation or No. (%).
- ^aThe effect sizes are standardized mean differences for continuous outcomes and the
- 563 Phi coefficient for dichotomous outcomes.
- 564 SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA_{1c}, glycated
- 565 hemoglobin; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol;
- 566 LDL-C, low-density lipoprotein cholesterol.

568 Table 2. Associations of breast cancer with incident myocardial infarction and

569 heart failure (n=251 277)

	HR (95% CI)	
Outcome	Breast cancer vs. Non-breast cancer	P value
Myocardial infarction		
Model 1 ^a	0.84 (0.74 to 0.95)	0.005
Model 2 ^b	0.83 (0.73 to 0.94)	0.002
Heart failure		
Model 1 ^a	1.24 (1.12 to 1.27)	< 0.001
Model 2 ^b	1.20 (1.09 to 1.33)	< 0.001

IID (050/ CI)

^aAdjusted for age, ethnicity, and education.

^bbFurther adjusted for current smoking, current drinking, obesity, exercise,

572 low-density lipoprotein cholesterol, depressed mood, hypertension, diabetes,

573 antihypertensive drug use, antidiabetic drug use, and statin use.

574 HR, hazard ratio; CI, confidence interval.

576 Table 3. Associations of age at breast cancer onset with incident myocardial

Outcome	HR (95% CI) ^a	P value
Myocardial infarction		
≥60 years (n=7930)	Reference	/
50-59 years (n=5637)	1.05 (0.78 to 1.40)	0.750
<50 years (n=2674)	2.20 (1.54 to 3.15)	< 0.001
Per 10-year decrease	1.36 (1.19 to 1.56)	< 0.001
Heart failure		
≥60 years (n=7930)	Reference	/
50-59 years (n=5637)	1.32 (1.07 to 1.64)	0.010
<50 years (n=2674)	1.68 (1.22 to 2.31)	0.001
Per 10-year decrease	1.31 (1.18 to 1.46)	< 0.001

577 infarction and heart failure among participants with breast cancer (n=16 241)

^aAdjusted for age, ethnicity, education, current smoking, current drinking, obesity,

579 exercise, low-density lipoprotein cholesterol, depressed mood, hypertension, diabetes,

580 antihypertensive drug use, antidiabetic drug use, and statin use.

581 HR, hazard ratio; CI, confidence interval.

583 Table 4. Associations of breast cancer with incident myocardial infarction and

heart failure among different onset age groups after propensity score matching 584

(n=64 964) 585

	(= = / = =)	
Outcome	Breast cancer vs. Non-breast cancer	P value
Myocardial infarction		
≥60 years (n=31 720)	0.75 (0.63 to 0.89)	0.001
50-59 years (n=22 548)	0.75 (0.58 to 0.97)	0.028
<50 years (n=10 696)	1.75 (1.21 to 2.52)	0.003
Heart failure		
≥60 years (n=31 720)	1.03 (0.90 to 1.19)	0.650
50-59 years (n=22 548)	1.38 (1.13 to 1.69)	0.002
<50 years (n=10 696)	2.21 (1.55 to 3.17)	< 0.001

HR (95% CI)^a

^aAdjusted for age, ethnicity, education, current smoking, current drinking, obesity, 586

exercise, low-density lipoprotein cholesterol, depressed mood, hypertension, diabetes, 587

antihypertensive drug use, antidiabetic drug use, and statin use. 588

HR, hazard ratio; CI, confidence interval. 589

591 Figure Legends

592 **Figure 1.** Flow chart of participant selection for this study

